Blog - Datapharm Australia

Parkinson’s Awareness Month: Advancing Research and Building a Stronger Clinical Trials Network in Australia

April is Parkinson’s Awareness Month—a time to shine a light on one of the fastest growing neurological conditions in the world. At Datapharm, we are proud to support ongoing efforts to improve the...

ICH GCP E6(R3) Update – What the Latest Version Means for Clinical Trials and Ethical Compliance

In the realm of clinical research, ethical oversight and scientific integrity are paramount. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use...

Literature Search Strategies in Pharmacovigilance for Post-Marketing/Approved Medicines

Data obtained from the medical and scientific literature is a key aspect of monitoring the safety profile and risk-benefit balance of medicines, as it can help identify new safety signals or safety...

Australian Cancer Research Oncology Clinical Trial Site Tour

Conducting cancer clinical trials in Australia involves a comprehensive and structured approach, guided by stringent regulatory standards, ethical considerations, and a commitment to high-quality...

2024 Update to the Declaration of Helsinki – Relevance for Clinical Trials and Ethical Standards

The Declaration of Helsinki, the globally recognised foundation for ethical guidelines in medical research involving human participants, was updated in October 2024. This revision is important for...

ICU Clinical Trials: Navigating Challenges in Critical Care Research

Clinical trials play a vital role in advancing medical knowledge and improving patient outcomes. However, conducting ICU clinical trials in an Intensive Care Unit (ICU) setting presents unique...

The Role of Technology in Data Capture for Post-Marketing Studies

Post-marketing studies, also known as Phase IV trials, are essential for evaluating the long-term safety and efficacy of drugs after they have received regulatory approval. These studies gather...

Let’s Connect and Collaborate with Datapharm CRO at local 2024 conferences in Australia!

Whether you’re attending PDC 2024, AusBioInvest 2024, AusBiotech National Conference 2024, or COSA ASM 2024, Datapharm Australia is excited to meet with you and explore how we can support your...

Running Phase IV Clinical Trials in Australia: Key Insights and Benefits

Phase IV clinical trials, often referred to as late-phase or post-marketing studies, play a crucial role in the drug development lifecycle. In Australia, the significance of conducting these trials...

Phase IIb Studies: Assessing Efficacy and Optimising Dosing in Clinical Trials

As a leading Australian CRO, Datapharm Australia specialises in managing Phase IIb clinical trials, a critical stage in drug development focused on assessing efficacy, safety, and optimising dosage. ...

SAD and MAD Studies in Early Phase Clinical Trials: Ensuring Drug Safety and Efficacy

As a leading Australian CRO, Datapharm Australia specialises in the critical early stages of clinical development, including Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) studies....

Clinical Monitoring in Early Phase Clinical Trials: Ensuring Data Integrity and Patient Safety

Early-phase clinical trials, encompassing Phase I and Phase IIa studies, are critical steps in the drug development process. These trials aim to evaluate the safety, tolerability, and...